About the Company
9 meters biopharma, inc., a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. the company's pipeline includes drug candidates for short bowel syndrome (sbs) and celiac disease. it is developing nm-002, a long-acting injectable glp-1 agonist that is in a phase 2 clinical trial for sbs; and larazotide, a phase 3-stage therapeutic in development for celiac disease. the company also develops nm-003, a proprietary long-acting glp-2 agonist; and nm-004, a double-cleaved mesalamine with an immunomodulator for developing rare and/or orphan indications. 9 meters biopharma, inc. is based in raleigh, north carolina.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NMTR News
9 Meters Biopharma, Inc. (NMTRQ)
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
After coeliac fail, 9 Meters plots phase 3 in short bowel syndrome
Two weeks after reporting disappointing results for its lead coeliac disease therapy, 9 Meters Biopharma will draw some comfort from a mid-stage trial of its candidate for short bowel syndrome ...
Nissim Darvish's Net Worth
This is based on reported shares across multiple companies, which include 9 METERS BIOPHARMA, INC., and Chemomab Therapeutics Ltd.. Attention insiders: Dive deeper into market movements and stay ...
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcript March ... In 2023, we successfully advanced this business and generated over $10 million in total revenue. I'm going to ...
ABVC BioPharma, Inc. Common Stock (ABVC)
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcript
Theravance Biopharma ... I’m pleased to report that our team delivered on these objectives. For both the fourth quarter and the full year, we increased the YUPELRI net sales 9% from $61 million ...
Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024
March 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus&CloseCurlyDoubleQuote ... will present at the Leerink Partners Global Biopharma Conference 2024 at 9:20 a.m. ET on Tuesday, March ...
9 Meters Biopharma Inc (NMTRQ)
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
9 Meters Biopharma Inc. (NMTRQ)
*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces ...
Loading the latest forecasts...